LenioBio Germany United States of America
03.09.2025 - 09:00:50LenioBio partners with AffinityAI to accelerate discovery of novel complex proteins through AI-guided design and high-throughput cell-free expression
LenioBio GmbH is a biotechnology company pioneering cell-free protein expression with its ALiCE® platform, enabling rapid discovery, development, and scalable production of proteins beyond the limits of living cells. Founded in Germany in 2016, LenioBio is headquartered in Düsseldorf with R&D and manufacturing facilities in Aachen. Learn more at www.leniobio.com and follow LenioBio on LinkedIn.
About AffinityAI
AffinityAI is a Danish biotechnology company specializing in AI-guided protein design. Its proprietary Designerbodies™ are fully synthetic, small proteins engineered to bind specifically to selected epitopes on target proteins. Designed and delivered significantly faster than traditional antibody discovery methods, Designerbodies™ have broad applications across drug development, diagnostics, and biomedical research. Headquartered in Copenhagen, AffinityAI works at the intersection of artificial intelligence and biotechnology to accelerate the next generation of therapeutic innovation. Learn more at affinityai.dk.
Media Contact:
Akanksha Ranjit
Marketing & Communications
LenioBio GmbH
a.ranjit@leniobio.com
Logo - https://mma.prnewswire.com/media/2735875/5486611/LenioBio_Logo.jpg
View original content:
